Akums Drugs & Pharmaceuticals is underscoring the clinical benefits and adaptability of lacosamide, positioning it as a leading treatment option for epilepsy.
The company highlights that this established antiepileptic drug (AED) is both effective and well-tolerated across diverse patient groups, including children and those with coexisting health conditions. Its availability in tablets, syrup, and injectable forms ensures continuity of care at home, in hospitals, and during emergencies.
Lacosamide’s distinct advantage lies in its unique mechanism of action. Unlike older sodium channel blockers that impact rapid neuronal firing, lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels, stabilizing overexcited neurons without affecting normal brain function. This precise targeting leads to fewer cognitive and systemic side effects, improving tolerability and adherence.
Clinical research demonstrates sustained seizure control for up to five years. In pediatric patients, including those under four, lacosamide has shown efficacy and tolerability, even in refractory epilepsy. The intravenous formulation is particularly valuable in urgent care, managing acute repetitive seizures and convulsive status epilepticus in critically ill children.
Its multi-formulation approach is especially important in India. The 15 mg/mL syrup helps patients who cannot swallow tablets, while the injectable form ensures continuity in hospital settings. Tablets in strengths ranging from 50 mg to 200 mg support individualized therapy and precise dose titration.
Lacosamide also shows benefits for patients with comorbidities. It has demonstrated comparable efficacy to carbamazepine-CR in psychiatric patients and proven safe for post-stroke epilepsy patients on anticoagulants. With a favorable safety record, including in sensitive populations like pregnant women, it is a reliable long-term therapy.
“Lacosamide is a reliable option for both monotherapy and adjunctive therapy, with clear potential to improve patient adherence and quality of life,” said Dr. Pooja Anand, consultant at Paras Health Gurugram.
By offering multiple routes of administration and flexible dosing, Akums reinforces its commitment to patient-centric neurology care. The company’s strategy supports modern healthcare needs, securing lacosamide’s position as a trusted therapy for epilepsy worldwide.